Today was one of those up-days that might be a disappointment to many bulls because the gap-ups were not met by follow-on buying throughout the day. A better weekly joblessness report may have been muted by Asian central banks intervening to protect the US Dollar.

Here are today's unofficial closing bell levels:

Dow 9,786.79 +61.21 (0.63%)
S&P 500 1,065.31 +7.73 (0.73%)
Nasdaq 2,124.41 +14.08 (0.67%)

Top analyst upgrades and downgrades
Top market rumors
Top day trader alerts

Today was one of those days where commodities and the dollar went all over. Gold still rose, yet oil fell on a very mixed inventory report. The markets started out with some strength, but the major indexes were mixed at the end of the day.

Here are today's unofficial closing bell levels:

Dow 9,725.80 -5.45 (-0.06%)
S&P 500 1,057.56 +2.84 (0.27%)
Nasdaq 2,110.33 +6.76 (0.32%)

Analysts: top upgrades and top downgrades
Top Rumors of the Day
Top Day Trader Alerts

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Aeropostale Inc. (NYSE: ARO) strong Q2 results beat expectations due to rising same-store sales.
• Agilent Technologies Inc. (NYSE: A) Q3 earnings topped low expectations and revenue declined.
• Analog Devices Inc. (NYSE: ADI) posted better-than-expected Q3 results but shares fell on weaker margins.
• Baidu Inc. (NASDAQ: BIDU) CEO said its new advertising efforts will boost sales over the long run.
• Barnes & Noble Inc. (NYSE: BKS) had a better-than-expected Q2 profit but same-store sales fell.
• BJ's Wholesale Club Inc. (NYSE: BJ) reported solid Q2 numbers and raised its full-year guidance.

Repros Therapeutics (NASDAQ: RPRX) easily takes the prize for most dismal earnings report of the day. Not only did the drug firm report a wider-than-forecast second-quarter loss, it also warned that bankruptcy is a real possibility unless the company can secure significant additional capital.

Specifically, Repros confessed to a second-quarter net loss of $8.9 million, or 59 cents per share, compared to Wall Street's consensus estimate for a loss of 46 cents per share. The company chalked up its poor results to a 16% annualized increase in clinical development activities for Proellex -- which has been placed on clinical hold by the FDA -- as well as a 60% year-over-year jump in general and administration expenses.